Abstract 3027
Background
Hereditary breast and ovarian cancer (HBOC) is one of the most frequent disorders among other cancers, caused by presence of germline pathogenic variants in patients. Awareness about presence of actionable mutations (BRCA1,2, ATM and others) is beneficial for patients with breast and ovarian cancer due to possibility of targeted treatment, monitoring risk groups among healthy carries and other aspects. In this study we reveal and characterize pathogenic germline mutations in HBOC patients from different regions in Russian Federation.
Methods
Individuals with “family history” were chosen to be included in this study according to the following criteria: (1) young age of disease onset, (2) the presence of relatives with breast or ovarian cancer diagnosis. Information about nationality, age at diagnosis, family cancer history, estrogen, progesterone and Her2 receptor status was collected. The NimbleGen SeqCap EZ Choice kit (“Roche”) was used for target enrichment, and sequencing was performed using Illumina MiSeq (“Illumina”) using paired-end 2 × 251 nucleotide single-index sequencing. HGMD Professional 2017.4 and BIC databases were used to identify pathogenic mutations.
Results
568 patients with breast or ovarian cancer aged from 21 to 82 years old were included in this study. 103 woman has their first cancer diagnosis before 40 years old, 305 – between 40 and 60 years old, 160 - were older than 60. 193 patients had first degree kinship relatives suffered from HBOC syndrome and 165 patients had relatives with other cancers. Of the 568 patients, 22,5% (128) carried pathogenic or likely pathogenic mutation in BRCA1 gene, 9,2% (52) in BRCA2 gene, 17,6% (100) in one of other HBOC related genes, including CDK12, ATM, CDH1, APC, FANCI, CHEK2, FANCL, BARD1, RAD51C, MUTYH, RAD51D, PALB2, FANCA, XRCC2, RAD54L, CHEK1.
Conclusions
Among patients with fulfilling NCCN criteria of hereditary breast or ovarian cancer, only 30% of cases might be explained by BRCA1 or BRCA2 mutation. Panel sequencing is powerful strategy to find variants in other genes, which may play a role in cancer development. It has to be noted that many variants in non-BRCA genes were identified is of unknown significance (VUS) due to absence of database with common variants for Russian population.
Clinical trial identification
Legal entity responsible for the study
Tatarstan Cancer Center.
Funding
The work is supported by the Russian Foundation for Basic Research № 18-415-160009 r_a and according to the Russian Government Program of Competitive Growth of Kazan Federal University.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract